Latest Regulatory Reviews News

TPC Consolidated and Wollar Solar Holding have agreed to extend key deadlines in their acquisition scheme as they await crucial FIRB approval, pushing the timeline into early 2026.

Yancoal Australia Ltd reported a sharp 61% drop in net profit for the first half of 2025 amid falling coal prices and supply chain disruptions, despite a 15% rise in production. The company declared a fully franked interim dividend and is advancing strategic acquisitions and sustainability initiatives.

Recce Pharmaceuticals has initiated patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, targeting a significant market with high diabetes prevalence. Interim results expected in early 2026 could accelerate regulatory approval and commercial launch.

Tuas Limited has reported a robust turnaround in FY25 with positive net profit and strong subscriber growth, alongside completing the strategic acquisition of M1 Limited. The company sets sights on further expansion amid regulatory review.

Clover Corporation posted a robust 38% revenue increase to $86 million in FY25, driven by product innovation and operational gains, while declaring a final dividend. The company’s cautious outlook for FY26 reflects ongoing regulatory and production challenges.

Renergen Limited and Springbok Solar Power Plant have resolved a protracted legal dispute over land use rights, enabling both the Virginia Gas and Springbok Solar projects to operate collaboratively in South Africa's Free State.

Cleo Diagnostics has received encouraging feedback from the U.S. FDA on its ovarian cancer pre-surgical triage test, reinforcing its clinical trial design and regulatory strategy ahead of a critical 510(k) submission.

The Takeovers Panel has declined to intervene in the Elanor Commercial Property Fund's takeover bid by LDR Assets, following resolution of disclosure concerns.

Elanor Commercial Property Fund has lodged an application with the Takeovers Panel, alleging significant disclosure deficiencies in Lederer’s off-market takeover bid and seeking a replacement bidder’s statement.

Lumos Diagnostics has secured a significant follow-on contract with Aptatek Biosciences to push forward the development of an innovative in-home monitoring device for Phenylketonuria (PKU), a rare genetic disorder. This next phase aims to bring the FDA Breakthrough Device-designated PheCheck™ closer to clinical trials and commercial readiness.

Island Pharmaceuticals has formally requested a Type C meeting with the US FDA to discuss accelerating approval of its antiviral Galidesivir for Marburg virus using the Animal Rule pathway.

Mad Paws Holdings has completed the divestment of its Pet Chemist business and announced the resignation of Executive Director Howard Humphreys, advancing its proposed acquisition by Rover Group.